Researchers who conducted the first clinical trial for Hydroxychloroquine as an early treatment for mild coronavirus illness have found that the drug was no better than a placebo in non-hospitalized patients. About 24% of the patients were given Hydroxychloroquine for over 14 days and about 30% of the patients were given placebo, both with persisting symptoms showed no significant difference statistically concluding that the drug did not reduce the symptom severity in patients with mild COVID-19.
Conditions of the patients were monitored for 14 days. At the end of two weeks, the team of researchers discovered that the drug had no significant effect, and offered no advantage in relieving the symptoms preventing the progression of COVID-19. The death rate was the same in the two groups, at 0.4 per cent. The FDA cautions against the use of Hydroxychloroquine and chloroquine outside of the hospital, based on the report released with regards to the safety issues related to the use of Hydroxychloroquine and chloroquine in patients with COVID-19. Although a vaccine is not found yet, many vaccine candidates are conducting clinical trials.